^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    LINC02446 (Long intergenic non-protein coding RNA 2446)

    i
    Other names: LINC02446 , Long intergenic non-protein coding RNA 2446, RP11-291B21.2-001
    Associations

    News

    Trials
    10ms
    The lncRNA LINC02446 promotes tumor progression and HLH occurrence by regulating the expression of KLRs and IL-10 in EBV-NK-LPDs. (PubMed, Int Immunopharmacol)
    This is the first study that LINC02446 regulates the expression of KLRs family and IL-10 in EBV-NK-LPDs, resulting in lymphoma progression and HLH occurrence, showing its potential as a therapeutic target for EBV-NK-LPDs.
    Journal
    |
    IL10 (Interleukin 10) • LINC02446 (Long intergenic non-protein coding RNA 2446)
    over1year
    lncRNA signature mediates mitochondrial permeability transition-driven necrosis in regulating the tumor immune microenvironment of cervical cancer. (PubMed, Sci Rep)
    The 6 key genes can serve as independent biomarkers for diagnosis, and the Risk score of these genes when acting together can be used as an indicator for predicting the clinical survival period of CESC patients. Additionally, these 6 key genes were closely related to the tumor immune microenvironment of CESC patients and were the important regulatory factors in the tumor immune microenvironment of CESC patients.
    Journal
    |
    CHRM3 (Cholinergic Receptor Muscarinic 3) • LINC02446 (Long intergenic non-protein coding RNA 2446)
    over2years
    A novel cuproptosis-related lncRNAs signature predicts prognosis in bladder cancer. (PubMed, Aging (Albany NY))
    Finally, quantitative RT-PCR showed that AC005261.1, AC021321.1, AL024508.2, LINC02446 and LINC01106 were lowly expressed in tumor cells, while ARHGAP5-AS1 showed the opposite trend. In summary, the predictive signature can independently predict the prognosis and provide clinical treatment guidance for BLCA patients.
    Journal
    |
    ARHGAP5 (Rho GTPase Activating Protein 5) • LINC02446 (Long intergenic non-protein coding RNA 2446)
    3years
    Ferroptosis-associated lncRNA prognostic signature predicts prognosis and immune response in clear cell renal cell carcinoma. (PubMed, Sci Rep)
    Immunity analysis proclaimed a striking difference in terms of cells, function, checkpoints, and ESTIMATE scores between low- and high-risk groups. Overall, the innovative signature of ferroptosis-associated signatures may have a considerable effect on the immune response and prognosis for ccRCC.
    Journal
    |
    IGF2 (Insulin-like growth factor 2) • LINC00460 (Long Intergenic Non-Protein Coding RNA 460) • IGFL2-AS1 (IGFL2 Antisense RNA 1) • LINC02446 (Long intergenic non-protein coding RNA 2446)
    over3years
    Identification of novel cuproptosis-related lncRNA signatures to predict the prognosis and immune microenvironment of breast cancer patients. (PubMed, Front Oncol)
    Finally, high-risk patients showed high sensitivity in anti-CD276 immunotherapy and conventional chemotherapeutic drugs such as imatinib, lapatinib, and pazopanib. We successfully constructed of a cuproptosis-related lncRNA signature, which can independently predict the prognosis of BC patients and can be used to estimate OS and clinical treatment outcomes in BRCA patients. It will serve as a foundation for further research into the mechanism of cuproptosis-related lncRNAs in breast cancer, as well as for the development of new markers and therapeutic targets for the disease.
    Journal • BRCA Biomarker • IO biomarker
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • CD276 (CD276 Molecule) • BRCA (Breast cancer early onset) • SYNE1 (Spectrin Repeat Containing Nuclear Envelope Protein 1) • LINC02446 (Long intergenic non-protein coding RNA 2446)
    |
    TMB-H • PIK3CA mutation • TMB-L
    |
    imatinib • lapatinib • pazopanib
    4years
    An immune-associated ten-long noncoding RNA signature for predicting overall survival in cervical cancer. (PubMed, Transl Cancer Res)
    The GSEA showed that the signature-related protein coding genes (PCGs) may participate in immunologic biological processes and pathways. This study revealed that the immune-associated ten-lncRNA signature is an independent factor for cervical cancer prognosis prediction, providing a bright future for immunotherapy of cervical cancer patients.
    Journal • IO biomarker
    |
    LINC02446 (Long intergenic non-protein coding RNA 2446)
    over4years
    Pivotal factors associated with the immunosuppressive tumor microenvironment and melanoma metastasis. (PubMed, Cancer Med)
    Elevated IL2RA, IL2RG, IL7R, and IFNG expression may play a central role in promoting melanoma metastasis through up regulation of intratumoral regulatory T-cell proportion mainly by activation of JAK-STAT signaling pathway. LINC02446, LINC01857, and LINC02384 may stimulate melanoma progression by reducing tumor-protecting miR.891a.5p and miR.203b.3p. A number of identified molecules including TNFRSF13B, LAG3, NRP1, ENTPD1, NT5E, CCL21, and CCR7 can serve as future therapeutic targets in melanoma treatment.
    Journal • IO biomarker
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8) • IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3) • TNFRSF17 (TNF Receptor Superfamily Member 17) • CD73 (5'-Nucleotidase Ecto) • IL2RA (Interleukin 2 receptor, alpha) • IL7R (Interleukin 7 Receptor) • TNFRSF9 (TNF Receptor Superfamily Member 9) • NT5E (5'-Nucleotidase Ecto) • CCR7 (Chemokine (C-C motif) receptor 7) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1) • NRP1 (Neuropilin 1) • LINC02446 (Long intergenic non-protein coding RNA 2446) • MIR203A (MicroRNA 203a) • TNFRSF11B (Tumor necrosis factor receptor superfamily member 11B)
    |
    IFNG expression
    almost5years
    Prediction of bladder cancer outcome by identifying and validating a mutation-derived genomic instability-associated long noncoding RNA (lncRNA) signature. (PubMed, Bioengineered)
    In addition, enrichment analysis indicated that GIlncSig is associated with genomic instability in bladder cancer. GIlncSig has a predictive value for the prognosis of bladder cancer patients and provides guidance for the clinical treatment of these patients.
    Journal
    |
    LINC02446 (Long intergenic non-protein coding RNA 2446)
    5years
    Long non-coding RNA LINC02446 suppresses the proliferation and metastasis of bladder cancer cells by binding with EIF3G and regulating the mTOR signalling pathway. (PubMed, Cancer Gene Ther)
    Additionally, we found that LINC02446 could bind to the EIF3G protein and regulate the protein stability of EIF3G and then inhibit the mTOR signalling pathway. In summary, all these findings show that LINC02446 might serve as a promising therapeutic target for BC intervention.
    Journal
    |
    LINC02446 (Long intergenic non-protein coding RNA 2446)
    5years
    An Epithelial-Mesenchymal Transition-Related Long Noncoding RNA Signature Correlates With The Prognosis And Progression In Bladder Cancer Patients. (PubMed, Biosci Rep)
    Functional enrichment analysis showed that EMT was associated with abundant GO terms or signaling pathways. In short, our research showed that the 14 EMT-related lncRNA signature may predict the prognosis and progression of bladder cancer patients.
    Clinical • Journal
    |
    LINC02446 (Long intergenic non-protein coding RNA 2446)